Cyrus Harmon
Net worth: 7 M $ as of 30/09/2026
Net worth: 7 M $ as of 30/09/2026
Dr. Cyrus L.
Harmon is a President & Chief Executive Officer at Vilya, Inc. and an Independent Director at Olema Pharmaceuticals, Inc. He is on the Board of Directors at Olema Pharmaceuticals, Inc. Dr. Harmon was previously employed as a General Manager by Affymetrix, Inc. and a Chief Executive Officer by Neomorphics, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from the University of California, Berkeley.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 24/07/2026 | 819,798 ( 0.94% ) | 7 M $ | 30/09/2026 |
| Companies | Position | Start |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Founder | 07/08/2006 |
Vilya Inc.
Vilya Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines to precise disease biology | Chief Executive Officer | 01/10/2023 |
| Companies | Position | End |
|---|---|---|
| AFFYMETRIX, INC. | Corporate Officer/Principal | 01/01/2002 |
Neomorphics, Inc.
Neomorphics, Inc. Medical SpecialtiesHealth Technology Develops, analyzes, and manages genetic information to improve disease | Chief Executive Officer | 01/01/2000 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Affymetrix, Inc.
Affymetrix, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and sells products and services for genetic analysis | Health Technology |
Neomorphics, Inc.
Neomorphics, Inc. Medical SpecialtiesHealth Technology Develops, analyzes, and manages genetic information to improve disease | Health Technology |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Vilya Inc.
Vilya Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines to precise disease biology | Health Technology |
Select your edition
All financial news and data tailored to specific country editions